Sahajanand Medical Technologies Limited (SMT) Q2 FY27: Record Revenue, Ebitda and PAT

Sahajanand Medical Technologies Limited (SMT) has reported its first results as a listed company with record-breaking Q2 FY27 results. The company’s revenue grew 25% to ₹7,251 crore, EBITDA surged 43% to ₹1,141 crore, and PAT increased 27% to ₹416 crore year-on-year. The Q2 FY27 quarter was the best yet, with the highest-ever quarterly revenue, EBITDA, and PAT. The company’s priorities remain disciplined execution, sustained investment in R&D, and better quality of cash flows.

Financial Highlights

In Q2 FY27, revenue grew 24.7% year-on-year to ₹3,734 crore, EBITDA rose 36.6% to ₹656 crore, and PAT increased 26.6% to ₹265 crore. The EBITDA margin expanded by 200 basis points to 17.6%.

Regional and Product Performance

The company’s revenue was driven by significant growth in other regions, which grew 42% in Q1 and 62% in Q2. The Rest of World (RoW) region, including APAC, RCIS, LATAM, and MEA, saw the fastest growth at 43% in Q1 and 32% in Q2, making up 40% of H1 revenue. India saw a 15% growth in Q2 after a 6% increase in Q1, while Europe remained steady with a 23% growth in both quarters.

Looking Ahead

SMT remains focused on improving margins through a richer product mix, vertical integration of critical components, better utilization of its plants, and tighter control of overheads to deliver profitable, sustainable growth.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sahajanand Medical Technologies Limited

Sahajanand Medical Technologies Limited. Here’s a quick read on where the business and the stock stand today.

Symbol SMT not found in TradeAlone database.